Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce
This article was originally published in The Pink Sheet Daily
Executive Summary
AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.
You may also be interested in...
EU's CHMP Clears Europe's First Gene Therapy, UniQure's Glybera
After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.
Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion
Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.
Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.